Ingrid Delaet insider trades: Neurocrine Biosciences (NBIX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ingrid reports to the SEC
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | NBIX | ↓ Sell | 14,571 | $178.65 | $2.6M | Direct | Jul 9, 2026 (0d) |
| May 29, 2026 | NBIX | ↓ Sell | 2,261 | $156.71 | $354K | Direct | Jun 2, 2026 (4d) |
| Jul 10, 2025 | NBIX | ↓ Sell | 457 | $135.00 | $62K | Direct | Jul 11, 2025 (1d) |
| Feb 13, 2025 | NBIX | ↓ Sell | 1,471 | $116.71 | $172K | Direct | Feb 14, 2025 (1d) |
| Feb 3, 2025 | NBIX | ↓ Sell | 1,045 | $150.81 | $158K | Direct | Feb 4, 2025 (1d) |
| Dec 31, 2024 | NBIX | ↓ Sell | 272 | $138.10 | $38K | Direct | Jan 3, 2025 (3d) |
| Dec 17, 2024 | NBIX | ↓ Sell | 1,091 | $135.00 | $147K | Direct | Dec 19, 2024 (2d) |
| Aug 13, 2024 | NBIX | ↓ Sell | 7,143 | $150.10 | $1.1M | Direct | Aug 15, 2024 (2d) |
| Aug 6, 2024 | NBIX | ↓ Sell | 273 | $147.70 | $40K | Direct | Aug 8, 2024 (2d) |
| Jul 16, 2024 | NBIX | ↓ Sell | 2,857 | $150.03 | $429K | Direct | Jul 18, 2024 (2d) |
| Jul 1, 2024 | NBIX | ↓ Sell | 272 | $138.11 | $38K | Direct | Jul 2, 2024 (1d) |
| May 31, 2024 | NBIX | ↓ Sell | 273 | $136.55 | $37K | Direct | Jun 4, 2024 (4d) |
| May 6, 2024 | NBIX | ↓ Sell | 273 | $140.55 | $38K | Direct | May 8, 2024 (2d) |
| Apr 1, 2024 | NBIX | ↓ Sell | 272 | $137.30 | $37K | Direct | Apr 3, 2024 (2d) |
| Mar 21, 2024 | NBIX | ↓ Sell | 5,000 | $145.06 | $725K | Direct | Mar 25, 2024 (4d) |
| Mar 13, 2024 | NBIX | ↓ Sell | 3,000 | $140.14 | $420K | Direct | Mar 15, 2024 (2d) |
| Mar 11, 2024 | NBIX | ↓ Sell | 2,000 | $140.03 | $280K | Direct | Mar 12, 2024 (1d) |
| Feb 29, 2024 | NBIX | ↓ Sell | 6,817 | $135.34 | $923K | Direct | Feb 29, 2024 (0d) |
| Feb 13, 2024 | NBIX | ↓ Sell | 716 | $133.03 | $95K | Direct | Feb 15, 2024 (2d) |
| Feb 1, 2024 | NBIX | ↓ Sell | 1,045 | $140.65 | $147K | Direct | Feb 2, 2024 (1d) |
| Aug 28, 2023 | NBIX | ↓ Sell10b5-1 | 1,431 | $107.52 | $154K | Direct | Aug 30, 2023 (2d) |
| Aug 21, 2023 | NBIX | ↓ Sell | 1,404 | $107.42 | $151K | Direct | Aug 23, 2023 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NBIX insiders
Open-market trades in the last 12 months
About Ingrid Delaet's insider trades
Ingrid Delaet is Chief Regulatory Officer at Neurocrine Biosciences (NBIX). Since Aug 21, 2023, Ingrid has reported no open-market purchases and 22 sales worth $8.1M on SEC Form 4. In the last 12 months: 2 sales ($3.0M).
1 sale (2% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include option exercises (20 filings), grants and awards (5 filings), shares withheld for taxes (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBIX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.